Notice of Results

RNS Number : 1931H

Shield Therapeutics PLC

15 August 2016

 

Shield Therapeutics plc

("Shield" or the "Company")

Notice of Interim Results

London, UK, 15 August 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces it will report its interim results for the six months ended 30 June 2016 on Tuesday 20 September 2016.

Carl Sterritt, Chief Executive Officer, Richard Jones, Chief Financial Officer, and Paul Steckler, VP  Commercial Operations, will host a presentation and live conference call for analysts at 11.00am BST on the morning of results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.

- Ends -

For further information please contact:

Shield Therapeutics plc	[phone]
Carl Sterritt, Chief Executive Officer Richard Jones, Chief Financial Officer
NOMAD Liberum Capital Limited Christopher Britton Steve Pearce	[phone]
Financial PR Advisor Consilium Strategic Communications	[phone] [e-mail]
Mary-Jane Elliott Matthew Neal Lindsey Neville Hendrik Thys

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Company has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA). In addition, the Company is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtherapeutics.com.

 

END

 

 

NORBBGDICBBBGLU